drugset / Trial / NCT07016490
A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors
Phase 1
Recruiting
15 enrolled
Shenyang Sunshine Pharmaceutical Co., LTD.
Macquarie University, Australia · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.
Timeline
- Start
- 2025-06-12
- Primary completion
- 2027-09-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SSGJ-709 | Unknown | — | Intravenous |